#USA #Houston #Breakthrough T1D #FINE-ONE Trial #Finerenone

Breakthrough in T1D Treatment: FINE-ONE Trial Results

The FINE-ONE phase 3 clinical trial, under the leadership of Bayer and presented at the American Society of Nephrology Kidney Week in Houston, has shown encouraging results in treating chronic kidney disease (CKD) in adults suffering from type 1 diabetes (T1D). The trial's findings indicate that finerenone, a non-steroidal mineralocorticoid receptor antagonist, significantly decreased the urine albumin-to-creatinine ratio (UACR) over a six-month period, which is critical in tracking kidney health and progress in CKD patients.

Chronic kidney disease is a major concern for those living with T1D, affecting nearly one-third of those diagnosed in their lifetime. The results from FINE-ONE suggest that treatment with finerenone can potentially delay the progression of CKD and reduce cardiovascular complications associated with this condition. This advancement is especially noteworthy, given that finerenone is already approved for treating adults with CKD linked to type 2 diabetes.

Dr. Jonathan Rosen, Research Director at Breakthrough T1D, expressed excitement about the trial's positive outcomes. He noted that kidney therapies addressing T1D have been limited, making the FINE-ONE trial a significant landmark. He praised Bayer for tackling an urgent unmet medical need with this pivotal phase 3 study and reaffirmed Breakthrough T1D's support for joint efforts in treating CKD in the T1D population.

Following the trial's success, Bayer is set to present these findings to health authorities for potential regulatory evaluation, paving the way for finerenone to expand its application to CKD associated with T1D. The necessity for such advancements in treatment can’t be understated, as living with T1D not only demands constant management of blood sugar levels but also carries risks for long-term complications, especially concerning organ health.

About Type 1 Diabetes
T1D is an autoimmune disorder that results in little to no insulin production by the pancreas, necessitating lifelong insulin therapy and increasing the risk of severe health issues, including kidney disease. Globally, approximately 9.5 million individuals are afflicted by this condition. While many associate T1D with childhood and adolescent diagnoses, it’s crucial to note that nearly half of new cases are diagnosed in adults. The impact of genetic and environmental factors in the disease's onset remains under investigation aiming for a deeper understanding of this complex condition.

Breakthrough T1D stands as the leading global organization advocating for T1D research and support, focusing on enhancing the daily lives of those affected while striving toward cures. Their commitment extends beyond mere research; they actively work with governmental entities to address issues impacting the T1D community and empower individuals managing the disease.

The progress made by the FINE-ONE trial, in collaboration with Bayer, marks a hopeful step forward for those with type 1 diabetes affected by kidney disease. Continued research and clinical studies are critical to finding effective therapies and improving patient outcomes in the face of such a debilitating condition.

Conclusion

The FINE-ONE trial results provide a beacon of hope to many living with T1D and CKD. As the medical community continues to explore innovative treatments, the findings underscore the importance of dedicated research efforts and collaborative endeavors aimed at improving the lives of those affected by these challenging chronic conditions. By bridging research gaps and advocating for effective therapies like finerenone, both Breakthrough T1D and Bayer are working towards a future where the adverse effects of T1D can be significantly mitigated, enhancing the quality of life for millions across the globe.